Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate

Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-posit...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Rausch, Jessica L., Boichuk, Sergei, Ali, Areej A., Patil, Sneha S., Lee, Donna M., Brown, Matthew F., Makielski, Kathleen R., Liu, Ying, Taguchi, Takahiro, Kuan, Shih-Fan, Duensing, Anette
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://ncbi.nlm.nih.gov/pubmed/27965460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13882
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia